- Home
- POOL vs RNA Comparison
POOL vs RNA Comparison
Compare POOL & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POOL | RNA |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5B | 10.9B |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | POOL | RNA |
|---|---|---|
| Price | $267.52 | $72.88 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 20 |
| Target Price | ★ $308.57 | $69.26 |
| AVG Volume (30 Days) | 785.9K | ★ 1.8M |
| Earning Date | 02-19-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 10.93 | N/A |
| Revenue | ★ $5,294,666,000.00 | $20,868,000.00 |
| Revenue This Year | $1.92 | $88.12 |
| Revenue Next Year | $3.49 | $18.11 |
| P/E Ratio | $24.03 | ★ N/A |
| Revenue Growth | N/A | ★ 106.27 |
| 52 Week Low | $226.10 | $21.51 |
| 52 Week High | $374.74 | $73.06 |
Technical Indicators
Market Signals| Indicator | POOL | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.70 | 65.68 |
| Support Level | $250.06 | $72.80 |
| Resistance Level | $267.17 | $73.06 |
| Average True Range (ATR) | 6.50 | 0.20 |
| MACD | -0.06 | -0.05 |
| Stochastic Oscillator | 87.05 | 70.45 |
Price Performance
Historical ComparisonAbout POOL Pool Corporation
Pool Corp distributes swimming pool supplies and related products. Its products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.